

Application Study: European Pharmaceuticals



This study assesses the credit quality of European pharmaceutical corporates, following the release of Scope's Rating Methodology for European Pharmaceutical Corporates on 16 January 2016. Seventeen corporates were selected from a wider peer group and represent a cluster of 'innovative' and 'generic' types, as well as different company sizes. None of these companies have been rated by Scope, therefore it has derived indicative credit assessments based on public information and without projecting into the future.

Scope Ratings expects the credit quality of most European pharmaceutical companies to continue to be at least stable over the coming two years. This is based on an increasingly positive 'innovative balance' (ability to replace negative patent expiry effects with newly approved products) as well as our perception of the good chances of realising above-GDP growth for the innovative arm. As already visible in 2015, late-stage pipelines continue to deliver on innovative content, enabling innovators to maintain high selling prices, at least in the US. Our positive view also reflects our belief that most larger companies have reasonable financial policies, which enable management to realise potential acquisitions, without jeopardising the rating.


In the case of the generic segment, we see more challenges compared to the innovative, as pricing pressures persist and players need to find profitable niches, or get ready for the 'biosimilars' opportunity, to stem the industry trend towards commoditisation.

Credit quality of assessed corporates

The credit quality of the corporates assessed varies widely, differing by the quality and protection of business risk profiles as well as by financial policy definitions. While large multinational pharmaceutical corporates can still attain very high ratings, smaller and less protected companies remain in the non-investment grade territory. Financial risk metrics are fairly independent from companies' relative sizes, although the larger ones are generally more profitable and cash-rich.

Figure 1 shows Scope's indicative assessment of the credit quality of selected European pharmaceutical corporates. Business and financial risk profiles are combined depending on the rating level (business risk profiles are weighted more for investment grade and vice versa), and finally determined by the rating committee.

Figure 1: Indicative credit assessment of selected corporates in wider peer group



Source: Scope Ratings

Analysts

Olaf Tölke
+49 69 979447 54
o.toelke@scoperatings.com

Business Development

Dr Florian Stapf
+49 30 27891 149
f.stapf@scoperatings.com

Press

Stephanie Schuler
+49 30 27891 150
s.schuler@scoperatings.com

Related Research

Rating Methodology: European Pharmaceuticals

January 2016

European Corporate Outlook,
February 2016

Scope Ratings AG

Lennéstraße 5
10785 Berlin

Phone +49 30 27891 0
Fax +49 30 27891 100
Service +49 30 27891 300

info@scoperatings.com
www.scoperatings.com

Bloomberg: SCOP

Main geographic focus	Europe
Inhouse specialist expertise	Yes
Production/distribution	EUR
First-to-file history	No
Products launched	23
Regulatory track record	good

Company in transition

Focused European/CIS player, diversified pharma company

Thin pipeline – flexible R&D approach

Good profitability

Excellent debt protection measures

Gedeon Richter plc ('Richter') is a generic company, but strongly committed to R&D and innovative drugs. It is the largest pharma company in Central and Eastern Europe (CEE). As a relatively small player on a global scale, Richter has a flexible approach between inhouse developed and in-licensed products. The business model focuses on only three treatment areas. Richter is the third-largest supplier with about 5% of the Hungarian pharma market, and is a significant player in female healthcare. The company also has a small wholesale and retail pharma business.

Business risk profile

Based on management's stated strategy, Richter sees itself as innovation-driven. This is reflected in the existing clinical pipeline and the recent approval of its anti-schizophrenia drug, VRAYLAR, in the US. However, its main commercial exposure is to off-patent generic products and the company is currently developing two biosimilars. Thus, judged by its present structure, we allocate Richter to the generic industry, although it is by no means a pure play. Based on our reasoning below, we view its business risk profile at a BBB.

Richter is CEE's biggest pharma. With about one-third of group sales in 2015, the CIS region continues its prominence. Western Europe and CIS accounted for almost 85% of group sales, while the US, Asia and emerging markets are underrepresented. Its product portfolio focuses on three important areas: gynaecology, CNS and cardiovascular, which account for about 70% of group sales combined. Richter's diversified group structure (innovative, generic, wholesale) provides another benefit from a rating assessment view.

In 2015, R&D spend was below 10% of revenues. We view this as in line with a generic company, but regarding its strategy to focus on innovation, it compares unfavourably to peers, in our view. The clinical pipeline appears to be thin, with 2 NMEs in late-stage development. However, it has led to the recent approval of a schizophrenia drug, a rather specialised treatment area. From a ratings point of view, we view positively the inhouse development of two biosimilar drugs, as competitive pressure is much less severe in this area compared to traditional generics. In 2014, Richter launched 23 new products, which compares unfavourably to peers.

Richter generated a relatively high EBITDA margin of 27% in 2015, strongly improving over 2014. If sustainable, we believe this will give strong support from a ratings point of view and compare favourably to peers.


Financial risk profile

The company continues to have a net cash position due to consistent, and even increasing, free cash flow generation over time, yielding a financial risk profile in the AAA category.

Scope's credit quality assessment

Figures in HUF m	2012	2013	2014	2015	in EUR m
Revenues	326,702	351,424	353,709	365,220	1,179
EBITDA	75,979	75,524	67,110	98,665	318
EBITDA margin	23.3%	21.5%	19.0%	27.0%	
Funds from operations (FFO)	73,182	76,253	60,066	92,022	297
Free cash flow (FCF)	12,604	15,278	24,131	66,511	215
Net debt	-28,194	-44,721	-39,260	-88,663	-286
FFO/net debt	-260%	-171%	-153%	-104%	
Net debt/EBITDA	0	-1	-1	-1	
FFO-interest cover	75,979	75,524	67,110	98,665	

Source: Gedeon Richter, Scope Ratings



Source: Scope Ratings



Application Study: European Pharmaceuticals

Scope Ratings AG

Headquarters Berlin

Lennéstraße 5
D-10785 Berlin

Phone +49 30 27891 0

London

Suite 407
2 Angel Square
London EC1V 1NY

Phone +44 20 3457 0444

Frankfurt am Main

Rüsterstraße 1
D-60325 Frankfurt

Phone +49 69 97944 754

Madrid

Paseo de la Castellana 95
Edificio Torre Europa
E-28046 Madrid

Phone +34 914 186 973

Paris

21, Boulevard Haussmann
F-75009 Paris

Phone +33 1 53 43 29 89

info@scoperatings.com

www.scoperatings.com

Disclaimer

© 2016 Scope Corporation AG and all its subsidiaries including Scope Ratings AG, Scope Analysis GmbH, Scope Investor Services GmbH (collectively, Scope). All rights reserved. The information and data supporting Scope's ratings, rating reports, rating opinions and related research and credit opinions originate from sources Scope considers to be reliable and accurate. Scope cannot however independently verify the reliability and accuracy of the information and data. Scope's ratings, rating reports, rating opinions, or related research and credit opinions are provided "as is" without any representation or warranty of any kind. In no circumstance shall Scope or its directors, officers, employees and other representatives be liable to any party for any direct, indirect, incidental or otherwise damages, expenses of any kind, or losses arising from any use of Scope's ratings, rating reports, rating opinions, related research or credit opinions. Ratings and other related credit opinions issued by Scope are, and have to be viewed by any party, as opinions on relative credit risk and not as a statement of fact or recommendation to purchase, hold or sell securities. Past performance does not necessarily predict future results. Any report issued by Scope is not a prospectus or similar document related to a debt security or issuing entity. Scope issues credit ratings and related research and opinions with the understanding and expectation that parties using them will assess independently the suitability of each security for investment or transaction purposes. Scope's credit ratings address relative credit risk, they do not address other risks such as market, liquidity, legal, or volatility. The information and data included herein is protected by copyright and other laws. To reproduce, transmit, transfer, disseminate, translate, resell, or store for subsequent use for any such purpose the information and data contained herein, contact Scope Ratings AG at Lennéstraße 5 D-10785 Berlin.